Literature DB >> 32007707

CTLA-4: From mechanism to autoimmune therapy.

Arezoo Hosseini1, Tohid Gharibi1, Faroogh Marofi2, Zohreh Babaloo3, Behzad Baradaran4.   

Abstract

CD28 and CTLA-4 are both important stimulatory receptors for the regulation of T cell activation. Because receptors share common ligands, B7.1 and B7.2, the expression and biological function of CTLA-4 is important for the negative regulation of T cell responses. Therefore, elimination of CTLA-4 can result in the breakdown of immune tolerance and the development of several diseases such as autoimmunity. Inhibitory signals of CTLA-4 suppress T cell responses and protect against autoimmune diseases in many ways. In this review, we summarize the structure, expression and signaling pathway of CTLA-4. We also highlight how CTLA-4 defends against potentially self-reactive T cells. Finally, we discuss how the CTLA-4 regulates a number of autoimmune diseases that indicate manipulation of this inhibitory molecule is a promise as a strategy for the immunotherapy of autoimmune diseases.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32007707     DOI: 10.1016/j.intimp.2020.106221

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  31 in total

Review 1.  Acute Kidney Injury Induced by Immune Checkpoint Inhibitors.

Authors:  Ruixue Tian; Jin Liang; Rongshan Li; Xiaoshuang Zhou
Journal:  Kidney Dis (Basel)       Date:  2022-04-04

Review 2.  Immune checkpoint inhibitors for the treatment of melanoma.

Authors:  Francesco Sabbatino; Luigi Liguori; Stefano Pepe; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2022-02-13       Impact factor: 5.589

Review 3.  Cervical Cancer Immunotherapy: Facts and Hopes.

Authors:  Louise Ferrall; Ken Y Lin; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Clin Cancer Res       Date:  2021-04-22       Impact factor: 12.531

Review 4.  Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review.

Authors:  M Jamee; S Hosseinzadeh; N Sharifinejad; M Zaki-Dizaji; M Matloubi; M Hasani; S Baris; M Alsabbagh; B Lo; G Azizi
Journal:  Clin Exp Immunol       Date:  2021-05-03       Impact factor: 5.732

Review 5.  Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?

Authors:  Negar Hosseinkhani; Afshin Derakhshani; Omid Kooshkaki; Mahdi Abdoli Shadbad; Khalil Hajiasgharzadeh; Amir Baghbanzadeh; Hossein Safarpour; Ahad Mokhtarzadeh; Oronzo Brunetti; Simon C Yue; Nicola Silvestris; Behzad Baradaran
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

6.  Reduced immune-regulatory molecule expression on human colonic memory CD4 T cells in older adults.

Authors:  Stephanie M Dillon; Tezha A Thompson; Allison J Christians; Martin D McCarter; Cara C Wilson
Journal:  Immun Ageing       Date:  2021-02-13       Impact factor: 9.701

7.  Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL).

Authors:  Pengcheng Feng; Hongxia Li; Jinhong Pei; Yan Huang; Guixia Li
Journal:  Front Genet       Date:  2021-02-10       Impact factor: 4.599

Review 8.  The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity.

Authors:  Yun-Shiuan Olivia Hsu; Kun-Lin Lu; Yun Fu; Chuang-Wei Wang; Chun-Wei Lu; Yu-Fen Lin; Wen-Cheng Chang; Kun-Yun Yeh; Shuen-Iu Hung; Wen-Hung Chung; Chun-Bing Chen
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 9.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

10.  Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.

Authors:  Chuiwen Deng; Wenli Li; Yunyun Fei; Li Wang; Yingying Chen; Xiaofeng Zeng; Fengchun Zhang; Yongzhe Li
Journal:  Front Immunol       Date:  2020-07-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.